Prescription drug · BLA
Nemluvio (nemolizumab-ilto) NDC 0299-6220
Nemolizumab 30 mg/100mg · Injection, Powder, Lyophilized, For solution · Subcutaneous · Galderma Laboratories, L.P.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0299-6220-10 | 00299622010 | 1 SYRINGE, GLASS in 1 CARTON (0299-6220-10) / 30 mg in 1 SYRINGE, GLASSMarketed from Aug 13, 2024 · Sample package | |
| 0299-6220-15 | 00299622015 | 1 SYRINGE in 1 CARTON (0299-6220-15) / 30 mg in 1 SYRINGEMarketed from Aug 13, 2024 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Nemluvio
- Generic name (nonproprietary)
- nemolizumab-ilto
- Active ingredients
- Nemolizumab — 30 mg/100mg
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Subcutaneous
- Labeler
- Galderma Laboratories, L.P.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761390
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-31 Receptor alpha Antagonists (Mechanism)
- Identifiers
- Product ID 0299-6220_df0e2be2-b6bd-40e5-9175-0c8e893433eaSPL ID df0e2be2-b6bd-40e5-9175-0c8e893433eaSPL set ID e9229ef1-ac60-4c24-afb6-009d3c781687RxCUI 2691325, 2691328UNII GN465U8B72
- Pharmacologic class
- Interleukin-31 Receptor alpha Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400299622010followed by a unit qualifier and the quantityPackage 00299-6220-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
NEMLUVIO is an interleukin-31 receptor antagonist indicated for: Prurigo Nodularis The treatment of adults with prurigo nodularis. ( 1.1 ) Atopic Dermatitis The treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. ( 1.2 ) 1.1 Prurigo Nodularis NEMLUVIO is indicated for the treatment of adults with prurigo nodularis. 1.2 Atopic Dermatitis NEMLUVIO is indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in c…
Excerpt only. Read the full label for complete information.